When diagnosed with cancer, most patients are pleased to hear that their disease is early-stage or low-grade – and most doctors are equally happy to deliver the news. But in endometrial cancer, that information doesn’t always bring the relief it would with other diagnoses. That’s because a subset of patients with early-stage, low-grade disease experience recurrence for unknown reasons, and those recurrences tend to resist further treatment. How do we know which patients are at risk of a return? We’ve had no way to tell – until now. Martina Bazzaro and her colleagues at the Masonic Cancer Center have uncovered a biomarker that could potentially predict these recurrences (1).

Read the full article now Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE and always will be! Login Email Password Forgot your password? Keep me logged in Log in Or register now - it’s free and always will be! You will benefit from: Unlimited access to ALL articles

News, interviews & opinions from leading industry experts

Receive print (and PDF) copies of The Pathologist magazine Register Or Login via Social Media Twitter By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Michael Schubert

While obtaining degrees in biology from the University of Alberta and biochemistry from Penn State College of Medicine, I worked as a freelance science and medical writer. I was able to hone my skills in research, presentation and scientific writing by assembling grants and journal articles, speaking at international conferences, and consulting on topics ranging from medical education to comic book science. As much as I’ve enjoyed designing new bacteria and plausible superheroes, though, I’m more pleased than ever to be at Texere, using my writing and editing skills to create great content for a professional audience.